drugset / Trial / NCT03507699
Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer
Phase 1
Completed
19 enrolled
Sheba Medical Center
Bristol-Myers Squibb · collabCheckmate Pharmaceuticals · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
A single institution study to evaluate the safety and tolerability of the combination treatment of nivolumab, ipilimumab, CMP-001 and radiosurgery in patients with metastatic colorectal cancer with liver metastases.
Timeline
- Start
- 2018-12-15
- Primary completion
- 2021-08-18
- Completion
- 2022-05-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Vidutolimod | Other / unclassified | 5 mg | Other |
| Subject | Vidutolimod | Other / unclassified | 10 mg | Other |